DE69309340T2 - Stabile Natrium-Porfimerzusammensetzungen und Verfahren zu ihrer Herstellung - Google Patents

Stabile Natrium-Porfimerzusammensetzungen und Verfahren zu ihrer Herstellung

Info

Publication number
DE69309340T2
DE69309340T2 DE69309340T DE69309340T DE69309340T2 DE 69309340 T2 DE69309340 T2 DE 69309340T2 DE 69309340 T DE69309340 T DE 69309340T DE 69309340 T DE69309340 T DE 69309340T DE 69309340 T2 DE69309340 T2 DE 69309340T2
Authority
DE
Germany
Prior art keywords
composition
compositions
preparation
ester
stable sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69309340T
Other languages
English (en)
Other versions
DE69309340D1 (de
Inventor
Stephen L Clauss
Michael J Pastel
Rainer K Zawadzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals Holdings Ireland ULC
Original Assignee
Quadra Logic Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Technologies Inc filed Critical Quadra Logic Technologies Inc
Publication of DE69309340D1 publication Critical patent/DE69309340D1/de
Application granted granted Critical
Publication of DE69309340T2 publication Critical patent/DE69309340T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE69309340T 1992-04-27 1993-04-27 Stabile Natrium-Porfimerzusammensetzungen und Verfahren zu ihrer Herstellung Expired - Lifetime DE69309340T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/873,860 US5244914A (en) 1992-04-27 1992-04-27 Stable porfimer sodium compositions and methods for their manufacture

Publications (2)

Publication Number Publication Date
DE69309340D1 DE69309340D1 (de) 1997-05-07
DE69309340T2 true DE69309340T2 (de) 1997-07-17

Family

ID=25362473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69309340T Expired - Lifetime DE69309340T2 (de) 1992-04-27 1993-04-27 Stabile Natrium-Porfimerzusammensetzungen und Verfahren zu ihrer Herstellung

Country Status (10)

Country Link
US (2) US5244914A (de)
EP (1) EP0568323B1 (de)
JP (1) JP2928047B2 (de)
KR (1) KR100221206B1 (de)
AT (1) ATE150968T1 (de)
CA (1) CA2094974C (de)
DE (1) DE69309340T2 (de)
DK (1) DK0568323T3 (de)
ES (1) ES2104056T3 (de)
GR (1) GR3023978T3 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7097826B2 (en) 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
JPWO2007142132A1 (ja) * 2006-06-02 2009-10-22 財団法人浜松科学技術研究振興会 ポルフィリン（ｙ）の多価金属化合物の新規製造方法
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8563012B2 (en) 2008-10-31 2013-10-22 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8568363B2 (en) 2008-10-31 2013-10-29 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
AU2014216112B2 (en) 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
MA47786A (fr) 2017-03-14 2020-01-22 Ohio State Innovation Foundation Méthodes et compositions se rapportant à des immunoconjugués igg3 ciblant le facteur tissulaire
KR102182630B1 (ko) 2019-12-19 2020-11-24 김진왕 친환경 스마트 광감작제 및 이를 포함하는 광줄기세포 치료제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4882234A (en) * 1986-11-12 1989-11-21 Healux, Inc. Storage-stable porphin compositions and a method for their manufacture
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5059619A (en) * 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester

Also Published As

Publication number Publication date
DE69309340D1 (de) 1997-05-07
KR930021143A (ko) 1993-11-22
KR100221206B1 (ko) 1999-10-01
CA2094974C (en) 1996-10-22
GR3023978T3 (en) 1997-10-31
ES2104056T3 (es) 1997-10-01
EP0568323B1 (de) 1997-04-02
JP2928047B2 (ja) 1999-07-28
DK0568323T3 (da) 1997-07-07
ATE150968T1 (de) 1997-04-15
EP0568323A1 (de) 1993-11-03
CA2094974A1 (en) 1993-10-28
US5244914A (en) 1993-09-14
US5438071A (en) 1995-08-01
JPH06220062A (ja) 1994-08-09

Similar Documents

Publication Publication Date Title
DE69309340D1 (de) Stabile Natrium-Porfimerzusammensetzungen und Verfahren zu ihrer Herstellung
EP0301781A3 (en) Cosmetic composition
AU8458891A (en) A process for the preparation of carnosic acid and the use of the acid for its anticarcinogenic and antiviral properties
ES8304239A1 (es) Un proceso de blanqueo de sustratos o de liquidos con un fotoactivador de porfina.
AU5150490A (en) Methods of preserving products and novel compositions therefor
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
MY110734A (en) Improvements in or relating to dioic acids.
GR3000417T3 (en) Fatty acid composition suitable for candle pressing
GR3003548T3 (de)
EP0463401A3 (en) Dispersant agent
GR3019315T3 (en) Use of nervonic acid and long chain fatty acids for the treatment of demyelinating disorders
DE69120505D1 (de) Verfahren zur Vorbereitung von Neotrehalose und seine Verwendungen
HK1003137A1 (en) New pyrazine derivatives their preparation and their use
ZA823248B (en) New anti-thromboticum based on polysacharides,method for its preparation and pharmaceutical compositions
HU903850D0 (en) Process for producing stable dried by freezing out poly-hematoporphyrinether/esther composition
DE3685052D1 (de) Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie.
AU5251893A (en) Lanolin/lanolin acid ester skin treatment composition
SE8800989D0 (sv) Dietary composition and process for preparing same
HK50094A (en) Skin detergent composition
DE3462656D1 (en) Use of sebosuppressive cosmetic products containing alkoxybenzoic esters
DE69032153T2 (de) Verfahren zur Herstellung von Butantetracarboxylat
JPS5536484A (en) Novel 1*44dihydropyridazinee33carboxylic acid derivative
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
EP0268037A3 (en) 3-tert-butyl- and, 3-tert-butyl-5-alkyl-4-hydroxyphenyl alcanoic acid ester with oxethylates of polyhydroxy aromatic compounds, process for their preparation and their use as stabilizer
IT1255373B (it) 5-nitro-metil-imidazolil-3-terbutil-2-idrossi- aril-carbinoli,un processo per la loro preparazione e relative composizioni terapeutiche.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AXCAN PHARMA (IRELAND)LTD., DUBLIN, IE